Abstract:As a consequence of a growing population of immunocompromised individuals, including transplant recipients and cystic fibrosis patients, there has been a dramatic increase in chronic infections caused by Mycobacterium abscessus complex (MABC) strains that are usually recalcitrant to effective antibiotic therapy. The recent rise of macrolide resistance in MABC has further complicated this clinical dilemma, dramatizing the need for novel agents. The repurposing of current antibiotics is one rapid path from discovery to patient care. In this study, we have discovered that dual beta-lactams, and specifically the combination of ceftazidime with either ceftaroline or imipenem, are synergistic and have clinically relevant activities, with MIC(50)s of 0.25 (ceftaroline with 100 mu g/ml ceftazidime) and 0.5 mu g/ml (imipenem with 100 mu g/ml ceftazidime) against clinical MABC isolates. Similar synergy was observed in time-kill studies against the M. abscessus ATCC 19977 strain using clinically achievable concentrations of either imipenem (4 mu g/ml) or ceftaroline (2 mu g/ml), as the addition of ceftazidime at concentrations of >= 50 mu g/ml showed a persistent bactericidal effect over 5 days. Treatment of THP-1 human macrophages infected with three different M. abscessus clinical isolates supported the in vitro findings, as the combination of 100 mu g/ml ceftazidime and 0.125 mu g/ml ceftaroline or 100 mu g/ml ceftazidime and 0.25 mu g/ml imipenem dramatically reduced the CFU counts to near baseline levels of infection. This study's finding that there is synergy between certain beta-lactam combinations against M. abscessus infection provides optimism toward identifying an optimum dual beta-lactam treatment regimen. IMPORTANCE The emergence of chronic MABC infections among immunocompromised populations and their inherent and acquired resistance to effective antibiotic therapy have created clinical challenges in advancing patients for transplant surgery and treating those with disease. There is an urgent need for new treatment regimens, and the repurposing of existing antibiotics provides a rapid strategy to advance a laboratory finding to patient care. Our recent discoveries that dual beta-lactams, specifically the combination of ceftazidime with ceftaroline or ceftazidime with imipenem, have significant in vitro MIC values and kill curve activities and are effective against infected THP-1 human macrophages provide optimism for a dual beta-lactam treatment strategy against MABC infections. The unexpected synergistic activities reported in this study create a new path of discovery to repurpose the large family of beta-lactam drugs.

Antibacterial action of penicillin against Mycobacterium avium complex

1866. Can β-lactam Combinations Restore Susceptibility Against Mycobacterium avium Complex: Exploring a New Approach to a “Difficult to Treat” Opportunistic Pathogen

The use of dual β-lactams to restore susceptibility of Mycobacterium avium complex

Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model

Activity of Antibiotics and Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium-intracellulare Complex Causing Chronic Pulmonary Infections

In Vitro Assessment of 17 Antimicrobial Agents Against Clinical Mycobacterium Avium Complex Isolates

Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro .

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System

Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients

[A study of beta-lactamase activity of mycobacteria and clinical trial of penicillin/beta-lactamase inhibitor combinations in the treatment of drug-resistant Mycobacterium tuberculosis]

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus

Regimen comprising clarithromycin, clofazimine and bedaquiline is more efficacious than monotherapy in a mouse model of chronic lung infection

Triple-Antibiotic Combination Exerts Effective Activity against Mycobacterium avium subsp. hominissuis Biofilm and Airway Infection in an In Vivo Murine Model

Synergistic Activity of Berberine with Azithromycin Against Pseudomonas Aeruginosa Isolated from Patients with Cystic Fibrosis of Lung in Vitro and in Vivo.

Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection

Combination of Imipenem-Cilastatin-Relebactam and Amoxicillin in the Antibiotic Regimen in Two Cases of Mycobacterium abscessus Lung Infection

Relationship between clarithromycin MICs and treatment responses in Mycobacterium avium complex pulmonary disease

Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease

Antimicrobial Susceptibility of Mycobacterium Abscessus Complex Clinical Isolates from a Chinese Tertiary Hospital.

Amikacin Liposome Inhalation Suspension As a Treatment for Patients with Refractory Mycobacterium Avium Complex Lung Infection

In vitro and intracellular activity of vaborbactam combined with β-lactams against Mycobacterium abscessus